Since DcR-2 and TRAIL-R2 are co-expressed in HNSCC tumors (60), the efficacy of TRAIL-mediated HNSCC therapy needs validation (34, 35). The gene discussed is TNFRSF10D; the disease is head and neck squamous cell carcinoma.